Duac Once Daily 10mg/g + 50mg/g Gel

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 22/01/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 15/5/2019

Click on this link to Download PDF directly

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Amoxil Paediatric Suspension Active Ingredients Amoxicillin trihydrate
Medicine Name Amoxil Vial for Injection 500mg Active Ingredients Amoxicillin sodium
Medicine Name ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Umeclidinium bromide, Vilanterol trifenatate
Medicine Name Augmentin 250 mg/125 mg film-coated tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 500mg/125mg Film-coated Tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 875/125mg Film Coated tablets Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Duo Mixed Fruit 400 mg/57 mg /5 ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin DUO Suspension 400/57mg Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin Intravenous 1.2g Active Ingredients Amoxicillin sodium, Potassium clavulanate
Medicine Name Augmentin Paediatric 125mg/31.25mg per 5ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name AVAMYS 27.5 micrograms/spray nasal spray suspension Active Ingredients Fluticasone furoate
Medicine Name Avodart Soft Capsules 0.5mg Active Ingredients Dutasteride
Medicine Name Babyhaler Active Ingredients No Active Ingredients
Medicine Name Bactroban Nasal Ointment Active Ingredients Mupirocin calcium
Medicine Name Bactroban Ointment Active Ingredients Mupirocin
Medicine Name Becotide Evohaler 100 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 250 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 50 Active Ingredients Beclometasone Dipropionate
Medicine Name Benlysta 120 mg and 400 mg powder for concentrate for solution for infusion Active Ingredients Belimumab
Medicine Name Betnovate C 0.1% / 3% w/w Cream Active Ingredients Betamethasone Valerate, Clioquinol
Medicine Name Betnovate Cream 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Ointment 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Cream Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Ointment Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Scalp Application 0.1% w/v Cutaneous Solution Active Ingredients Betamethasone Valerate
1 - 0 of 138 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 15 May 2019 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text
  • Improved presentation of SmPC

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7 - To amend the Irish Marketing Authorisation Holder (MAH) address.

Approved on 15 Decemeber 2015.  We are only updated the SPC from a word file to a pdf file to keep within the recent changes on Medicines.IE.

Updated on 22 January 2019 PIL

Reasons for updating

  • New PIL for new product

Updated on 4 January 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 4 January 2016 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7: Amend the MAH address

Updated on 27 January 2015 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.5 - spelling ‘sulphonamide’ to ‘sulfonamide’
Section 4.8 - addition of the PV reporting

Updated on 11 March 2013 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.3 - Preclinical safety data

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.1  Therapeutic indications

The following indication was amended Duac Once Daily Gel is indicated for the topical treatment of mild to moderate acne vulgaris, particularly inflammatory lesions

to add , in adults and adolescents aged 12 years and above (see sections 4.4 and 5.1).

 

The following statement was added:

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

 

4.2 Posology and method of administration

The wording was amended from:

For application to the skin. For external use only.

 

to:

For cutaneous use only.

 

The following section on Posology was updated from:

Adults and Adolescents

Duac Once Daily Gel should be applied once daily in the evening, to affected areas after the skin has been thoroughly washed, rinsed with warm water and gently patted dry.

Use in Children

The safety and efficacy of Duac Once Daily Gel has not been established in prepubescent children (under 12 years of age), since acne vulgaris rarely presents in this age group.

Use in the Elderly

No specific recommendations.

Treatment with Duac Once Daily Gel should not exceed more than 12 weeks of continuous use.

Hands should be washed after application

 

To:

 Adults and Adolescents (aged 12 years and above)

Duac Once Daily Gel should be applied once daily in the evening, to the entire affected area.

Patients should be advised that excessive application will not improve efficacy, but may increase the risk of skin irritation. If excessive dryness or peeling occurs, frequency of application should be reduced or application temporarily interrupted (see section 4.4).

An effect on inflammatory and non-inflammatory lesions may be seen as early as week 2-5 of treatment (see section 5.1).

The safety and efficacy of Duac Once Daily Gel has not been studied beyond 12 weeks in acne vulgaris clinical trials. Treatment with Duac Once Daily Gel should not exceed more than 12 weeks of continuous use.

Paediatric population

The safety and efficacy of Duac Once Daily Gel has not been established in children under 12 years of age, therefore Duac Once Daily Gel is not recommended for use in this population.

Elderly patients

No specific recommendations.

Method of administration

Duac Once Daily Gel should be applied in a thin film after washing gently with a mild cleanser and fully drying. If the gel does not rub into the skin easily, too much is being applied.

Hands should be washed after application.

 

 

4.4       Special warnings and precautions for use

The following paragraph was updated to read:

Contact with the mouth, eyes, lips, other mucous membranes or areas of irritated or broken skin should be avoided. Application to sensitive areas of skin should be made with caution. In case of accidental contact, rinse well with water.

 

The following was deleted:

It should also be used with caution in atopic patients, in whom further skin drying may occur.

 

The frequency of application should be reduced if excessive irritation or dryness develops.

 

The following was added:

Duac Once Daily Gel should be used with caution in atopic patients, in whom further skin drying may occur.

During the first weeks of treatment, an increase in peeling and reddening will occur in most patients. Depending upon the severity of these side effects, patients can use a non-comedogenic moisturiser, temporarily reduce the frequency of application of Duac Once Daily Gel or temporarily discontinue use however; efficacy has not been established for less than once daily dosing frequencies.

Concomitant topical acne therapy should be used with caution because a possible cumulative irritancy may occur, which sometimes may be severe, especially with the use of peeling, desquamating, or abrasive agents.

If severe local irritancy (e.g. severe erythema, severe dryness and itching, severe stinging/burning) occurs, Duac Once Daily Gel should be discontinued.

As benzoyl peroxide may cause increased sensitivity to sunlight, sunlamps should not be used and deliberate or prolonged exposure to sun should be avoided or minimised. When exposure to strong sunlight cannot be avoided, patients should be advised to use a sunscreen product and wear protective clothing.

If a patient has sunburn, this should be resolved before using Duac Once Daily Gel.

 

The following was deleted:

It is recommended that exposure to sun or sunlamps should be minimised.

 

Patients should be advised that, in some cases, 4-6 weeks of treatment may be required before the full therapeutic effect is observed.

 

The following was added:

Resistance to clindamycin

Patients with a recent history of systemic or topical clindamycin or erythromycin use are more likely to have pre-existing anti-microbial resistant Propionibacterium acnes and commensal flora (see section 5.1).

Cross-resistance

 

The following was deleted:

Local recommendations about antibiotic use and prevalence of acquired resistance should be taken into consideration.

 

4.5       Interaction with other medicinal products and other forms of interaction

The following was added:

No formal drug-drug interaction studies have been performed with Duac Once Daily Gel.

 

Duac Once Daily Gel should not be used in combination with erythromycin-containing products due to possible antagonism to the clindamycin component.

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore caution should be exercised with concomitant use.

 

The following was updated from:

 application of Duac Once Daily Gel and topical acne preparations containing vitamin A derivatives should be avoided.

 

 to:

Concomitant application of Duac Once Daily Gel with tretinoin, isotretinoin and tazarotene should be avoided

 

The following was updated from:

Potential synergism exists between clindamycin and gentamycin.

to:

since benzoyl peroxide may reduce their efficacy and increase irritation. If combination treatment is required, the products should be applied at different times of the day (e.g. one in the morning and the other in the evening).

Using topical benzoyl peroxide-containing preparations at the same time as topical sulphonamide-containing products may cause skin and facial hair to temporarily change colour (yellow/orange).

 

4.6       Fertility, pregnancy and lactation

The following sentence was added to the paragraph on Pregnancy:

There are limited data on the use of clindamycin and benzoyl peroxide alone in pregnant women.

The following section on Breastfeeding was updated from:

There are no contraindications in women of child-bearing potential who are practising adequate contraception.  However, due to the lack of clinical studies in pregnant women, Duac Once Daily Gel should be used with caution when adequate contraception is not being practised.

 

Use during lactation

There is no restriction on the use of benzoyl peroxide during lactation.

It is not known whether clindamycin is excreted in human milk following the use of Duac Once Daily Gel, but oral and parenteral administration of clindamycin has been reported to result in the appearance of clindamycin in breast milk.  For this reason, treatment of nursing mothers with Duac Once Daily Gel is not recommended.

 

To:

Use of Duac Once Daily Gel has not been studied during breastfeeding.

Percutaneous absorption of clindamycin and benzoyl peroxide is low however; it is not known whether clindamycin or benzoyl peroxide is excreted in human milk following the use of Duac Once Daily Gel. Oral and parenteral administration of clindamycin has been reported to result in the appearance of clindamycin in breast milk. For this reason, Duac Once Daily Gel should be used during lactation only if the expected benefit justifies the potential risk to the infant.

 

To avoid accidental ingestion by the infant if used during lactation, Duac Once Daily Gel should not be applied to the breast area.

 

The following section on Fertility was added:

Fertility

There are no data on the effect of Duac Once Daily Gel on fertility in humans.

 

4.8       Undesirable effects

The following section was updated from:

Duac Once Daily Gel may cause:

 

Skin and Subcutaneous Tissue Disorders; erythema, peeling, dryness, and pruritus at the site of application.

 

Very rarely:

Nervous System Disorders; paraesthesia,

Skin and Subcutaneous Tissue Disorders; worsening of acne and contact dermatitis can occur.

These localised effects are typically mild to moderate.  Reported frequencies in clinical trials are:

 

Very common (>1/10)

Skin and Subcutaneous Tissue Disorders; Erythema, Peeling, Dryness

 

Common (>1/100, <1/10)

Skin and Subcutaneous Tissue Disorders; Burning, Pruritus


Uncommon (>1/1000, <1/100)          

Nervous System Disorder; Paraesthesia

Skin and Subcutaneous Tissue Disorders; Worsening of acne

 

Post marketing data have shown a much lower incidence of these localised effects.

In a few susceptible individuals there have been isolated reports of pseudomembraneous colitis or diarrhoea due to other topical treatments containing clindamycin.  This is unlikely to occur with Duac Once Daily Gel, as plasma levels have been determined and the percutaneous absorption of clindamycin is clinically negligible.

 

With long term use of Duac Once Daily Gel resistance may occur.

 

Immune System Disorders

In the post-marketing environment there have been isolated instances of allergic reactions which can be sudden and severe.

 

To:

Adverse drug reactions (ADRs) are summarised below for Duac Once Daily Gel as a combination including any additional ADRs that have been reported for the single topical active ingredients, benzoyl peroxide or clindamycin. Adverse drug reactions are listed by MedDRA system organ class and by frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1,000 and <1/100), rare (≥1/10,000 and <1/1,000) and not known (cannot be estimated from the available data).

 

MedDRA SOC

Very Common

Common

Uncommon

Not known**

Immune system disorders

 

 

 

Allergic reactions including hypersensitivity and anaphylaxis

Nervous system disorders*

 

 

Paraesthesia

 

Gastrointestinal disorders

 

 

 

Colitis (including pseudomembranous colitis), haemorrhagic diarrhoea, diarrhoea, abdominal pain

Skin and subcutaneous tissue disorders*

Erythema, peeling, dryness

(Generally reported as ‘mild’ in severity)

Burning sensation

Dermatitis, pruritus, erythematous rash, worsening of acne

Urticaria

General disorders and Administration site conditions

 

 

 

Application site reactions including skin discoloration

*At site of application. **Based on post-marketing reports. Since these reports are from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency however, systemic reactions are rarely seen.

In addition to the ADRs reported in the table above, in the pivotal trial conducted with topical clindamycin 1%/benzoyl peroxide 3% gel, application site photosensitivity reaction was also reported commonly.

Also in addition to the ADRs reported above, in studies conducted with topical clindamycin alone, headache and application site pain were reported commonly.


Local Tolerability

During the five clinical trials with Duac Once Daily Gel, all patients were graded for facial erythema, peeling, burning, and dryness on the following scale: 0 = absent, 1 = mild, 2 = moderate and 3 = severe. The percentage of patients that had symptoms present before treatment (at baseline) and during treatment were as follows:

Local Tolerability Assessments for Subjects (N=397) in the Duac Once Daily Gel Group during the Phase 3 Studies

 

Before Treatment (Baseline)

During Treatment

 

Mild

Moderate

Severe

Mild

Moderate

Severe

Erythema

28%

3%

0

26%

5%

0

Peeling

6%

<1%

0

17%

2%

0

Burning

3%

<1%

0

5%

<1%

0

Dryness

6%

<1%

0

15%

1%

0

 

 

4.9       Overdose

 

This section was amended to :

Excessive application of Duac Once Daily Gel may result in severe irritation. In this event, discontinue use and wait until the skin has recovered.

Topically applied benzoyl peroxide is not generally absorbed in sufficient amounts to produce systemic effects.

Excessive application of topically applied clindamycin may result in absorption of sufficient amounts to produce systemic effects.

In the event of accidental ingestion of Duac Once Daily Gel, gastrointestinal adverse reactions similar to those seen with systemically administered clindamycin may be seen.

Appropriate symptomatic measures should be taken to provide relief from irritation due to excessive application.

Accidental ingestion should be managed clinically or as recommended by the National Poisons Centre, where available.

 

5.1       Pharmacodynamic properties

 

Additional paragraph added:

An effect on inflammatory lesions was apparent from week 2 of treatment. The effect on non-inflammatory lesions was more variable, with efficacy generally apparent after 2-5 weeks of treatment.

Updated on 15 May 2012 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The new SPC includes changes to section ‘6.5 Nature and Contents of Container’ where a new pack size has been added

Updated on 18 August 2011 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 Transfer of Marketing Authorisation from Stiefel Laboratories (UK) Ltd to GSK (Ireland) Ltd (Trading as Stiefel).

Updated on 12 October 2009 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

In Section 7.0 address of MAH has been amended to:

Stiefel Laboratories (UK) Ltd
Eurasia Headquarters
Concorde Road
Maidenhead
Berks SL6 4BY
United Kingdom

Updated on 8 February 2009 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 1: Name changed from "Duac Once Daily Gel" to  "Duac Once Daily 10mg/g + 50mg/g Gel"
 
Section 9: Renewal date added (16 September 2008)
 
Section 10: Date updated to January 2009
 
 

Updated on 28 August 2007 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Amended:
1) Pack sizes available
2) Date of Revision of the text
 

Updated on 6 July 2007 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Added:
In the post-marketing environment there have been isolated instances of allergic reactions which can be sudden and severe.

Updated on 17 March 2007 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 1 September 2006 SmPC

Reasons for updating

  • Correction of spelling/typing errors
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2 Changed 10mg clindamycin phosphate to 10mg clindamycin
Section 5.1 Changed ATC code.  Added paragraph starting "The prevalence...

Updated on 16 August 2005 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)